Most encouraging to see an analyst suggest that Vascepa has a potentially massive market in Europe.
No, no it’s not. Not when Goldman, JPM, Jefferies and Cantor currently remain silent on EU models and price targets regarding EU approval. These banks where involved in a $400 million cash raise at what price? And our stock trade today at what price? The appeals does not merit ignoring EU. Collusion to short AMRN is a federal crime.